Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11320453 | 0.93 | — | — | |
| SCHEMBL28254908 | 0.88 | EPHX1 (0.50) | ACHEGAAEPHX1 | |
| Ethylene Glycol SCHEMBL9551159 | 0.83 | ACHE (0.38) | ACHEGAAEPHX1 | |
| SCHEMBL720346 | 0.83 | — | — | |
| SCHEMBL722043 | 0.80 | EPHX1 (0.64) | ACHEEPHX1 | |
| SCHEMBL10113926 | 0.80 | ACHE (0.41) | ACHEEPHX1 | |
| SCHEMBL7185924 | 0.78 | EPHX1 (0.38) | ACHEGAAEPHX1 | |
| SCHEMBL723173 | 0.78 | EPHX1 (0.68) | ACHEEPHX1 | |
| SCHEMBL721745 | 0.78 | EPHX1 (0.68) | ACHEEPHX1 | |
| SCHEMBL18641585 | 0.78 | EPHX1 (0.68) | ACHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227787-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | ACHE 2955/4885GAA 526/4885EPHX1 1269/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | ACHE 3712/4885GAA 394/4885EPHX1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.